Prior notification of a concentration

(Case M.10611 – GENERALI FRANCE / LA MÉDICALE)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 111/04)

1. On 28 February 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— Generali France S.A. ('Generali France'), belonging to the Generali Group, ultimately controlled by Assicurazioni Generali S.p.A. (Italy),

— La Médicale S.A. ('La Medicale', France), controlled by Crédit Agricole S.A. ('Credit Agricole', France).

Generali France will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of La Médicale and of a portfolio of death covers and irreversible loss of autonomy covers insured by Predica Prévoyance Dialogue du Crédit Agricole S.A., a subsidiary of Crédit Agricole S.A., and marketed by La Médicale (the 'Insurance Portfolio') ([2]).

The concentration is accomplished by way of purchase of shares and purchase of assets.

2. The business activities of the undertakings concerned:

— Generali France is part of the Generali Group, an international group of companies active in the insurance and financial sector across the world. Generali France provides and distributes both life and non-life insurance products,

— La Médicale is a French specialist insurer for healthcare professionals active in France and Monaco. It provides non-life insurance products and focuses on medical liability insurance. La Médicale offers a number of additional products, such as personal injuries, motor vehicle, property, liability, and legal insurance. La Médicale currently markets the Insurance Portfolio and the Insurance Portfolio will also be part of the acquisition carried out by Generali France.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 ([3]) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10611 – GENERALI FRANCE / LA MÉDICALE

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').

([2]) The acquisitions by Generali France of La Médicale and the Insurance Portfolio constitute a single concentration pursuant to Article 3 of the Merger Regulation.

([3]) OJ C 366, 14.12.2013, p. 5.

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË